abbott laboratories news - Search News

Abbott Laboratories Stock Was a Winner

Seeking Alpha · 16h

Abbott Laboratories: It's No Longer A Buy For Now

Abbott Laboratories is showing strong growth potential with rising sales and EPS, though slightly overvalued. See why we are neutral on ABT stock.

Abbott Laboratories (ABT) Stock: More Robust Than the Numbers Suggest?

On Wednesday, Abbott Laboratories (ABT) stock saw a modest uptick, ending the day at $117.82 which represents a slight increase of $1.77 or 1.53% from the prior close of $116.05. The stock opened at $118.

The Motley Fool on MSN · 13h

Is Abbott Laboratories Stock a Buy?

If a company's history and track record were good enough reasons to buy its shares, it'd be easy to make a case for investing in Abbott Laboratories (NYSE: ABT). Abbott is a longtime leader in the healthcare sector, and has generally delivered excellent returns to long-term shareholders.

Abbott Narrows 2024 Forecast

Bloomberg on MSN · 1d

Abbott Narrows 2024 Forecast as Diabetes Devices Drive Sales

Abbott Laboratories narrowed its full-year profit outlook, raising the midpoint slightly, as strong demand for its diabetes devices continued driving growth.

Reuters on MSN · 1d

Abbott bumps up profit forecast on strong medical device sales

Abbott Laboratories slightly lifted its annual profit forecast on Wednesday, after beating Wall Street estimates for quarterly earnings on strong demand for its continuous glucose monitors (CGMs) and other medical devices.

U.S. News & World Report · 1d

Abbott Slightly Raises Profit Forecast on Strong Medical Device Sales

(Reuters) - Abbott Laboratories slightly lifted its annual profit forecast on Wednesday, after beating Wall Street estimates for quarterly earnings on strong sales of its medical devices including its glucose-monitoring products.

4h

Abbott Labs Path To Double-Digit Earnings Growth In 2025? This Analyst Is Optimistic

On Wednesday, Abbott Laboratories (NYSE:ABT) reported third-quarter sales of $10.64 billion, up 4.9% year over year, beating ...

15h

Abbott Laboratories: Buy Rating Reaffirmed Amid Strong Medical Device Performance and Positive Long-Term Growth Outlook

Analyst Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report) and keeping the price ...

1d

High-Quality Abbott Stock: Corporate Growth That Pays You to Own It

Abbott Laboratories is the #1 healthcare stock to own for consistent, market-beating returns over the long term. Q3 results ...

1d

Abbott Laboratories posts Q3 beat, raises profit forecast

Abbott Laboratories (ABT) shares tick into positive territory in Wednesday's pre-market trading on its third quarter earnings ...

13h

Abbott Laboratories: Strong Buy Rating Driven by Robust Growth Prospects and Operational Improvements

Bernstein analyst Lee Hambright maintained a Buy rating on Abbott Laboratories (ABT – Research Report) yesterday and set a price target ...

2don MSN

Jim Cramer Says That FDA, NIH, and CDC Comments On Abbott Laboratories (ABT) Could Potential Help The Stock Going Forward

We recently compiled a list of the Jim Cramer is Talking About These 14 Stocks Before Earnings. In this article, we are going ...

3d

Abbott: Challenging Comparables, Unappealing Value Limit The Incentive To Go Long Ahead Of Q3 Event

Abbott Laboratories' Q3 earnings and topline growth largely expected to be in line with the Q2 trend. Find out whether ABT ...

1d

Abbott Laboratories: Balanced Prospects Lead to Hold Recommendation Amid Market Adjustments

Morgan Stanley analyst Patrick Wood maintained a Hold rating on Abbott Laboratories (ABT – Research Report) today and set a price target ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results